原发性肝癌术后肝动脉栓塞化疗对防治复发的临床价值

目的探讨术后经胆管肝动脉栓塞化疗（TACE）对肝癌切除术后防治复发的作用。方法2000年1月～2003年1月间天津医科大学肿瘤医院肝胆外科对561例原发性肝癌患者行手术切除治疗，其中113例患者为观察组（A组），术后接受了TACE防治复发，每3周1次，共行4次；其余448例未行TACE治疗者作为对照组（B组）。结果A、B两组在性别、年龄、Child—pugh分级、术中失血量及其他临床病理学特征差异均无显著性。A、B两组的1年无瘤生存率分别为81．8％和80．9％，无明显差别；2年无瘤生存率为73．5％和67．8％，A组虽较B组高但无统计学意义（P〉0．05）；3年无瘤生存率为65.5％和49．2％，相比较具明显统计学差异（P〈0．05）。结论术后规律行TACE可以增加肝癌患者术后的无瘤生存率。     

原发性肝癌经肝动脉栓塞化疗后施行肝切除术的评价

迄今，肝切除术仍是公认的治疗原发性肝癌最有效的方法[1]。然而问题是，日常临床工作中所遇到的肝癌病例，属于小肝癌的病例很少，大多数属大肝癌，或特大肝癌[2]。相对而言，大肝癌或特大肝癌的切除术，困难大、出血多，使很多医生望而生畏，以致于不少大肝癌病例因未能得到有效的手术切除而失去了延长生命的机会。随着肝动脉栓塞化疗（HAEC）技术的普遍开展，已使一批经过此方法治疗的大肝癌患者症状缓解、生命延长，也使一部分病人的肿瘤缩小，而有利于手术切除。然而，关于原发性肝癌经HAEC后施行肝切除术的评价，文献中的意见存在…     

肝动脉、门静脉化疗栓塞对防治肝癌复发的价值

原发性肝癌是我国常见的消化道恶性肿瘤。随着医学检测手段的发展，肝癌检出率较前增高。肝癌病人术后的高复发率是严重影响其生存期的重要原因。如何早期发现和防治肝癌复发已成为肝癌治疗研究的重要课题之一。我院1990年1月起开展肝切除同时置皮下泵行肝动脉门静脉化疗栓塞的瞻前性临床研究。旨在探索防治肝癌术后复发的有效方法。     

预防性肝动脉化疗栓塞对大肝癌切除术后生存率的影响

目的：探讨预防性肝动脉化疗栓塞对大肝癌切除术后生存率的影响。方法：对比分析术后预防性肝动脉化疗栓塞组（观察组，32例）及单纯对症支持治疗组（对照组，17例）的1，3年生存率，结果：观察组一年生存率85．5％，三年生存率50．8％，对照组一年生存率39．7％，最长生存14个月，差异显（P＜0．05），结论：大肝癌切除术后预防性肝动脉化疗栓塞有效地提高了病人生存率。     

肝动脉化疗栓塞术治疗原发性肝癌后肝纤维化指标的改变

目的 探讨肝癌（HCC）经多次肝动脉化疗栓塞术（TACE）后是否加快肝纤维化的发展趋势。方法 选择20例原发性肝癌（HCC）首诊病人，共行3次TACE术，手术间隔时间为1个月，定期测量肝纤维化4项指标：透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PCⅢ）、Ⅳ型胶原（Ⅳ.C）的含量，并选取20例健康人测量以上指标作为对照。结果 经统计检验发现HCC病人肝纤维化4项指标较正常人明显升高（P＜0.05)，TACE术后4项指标呈进行性增高，第2次TACE术后1个月复查变化明显（P＜0.05)，第3次TACE术后复查指标变化最为显著（P＜0.01)。结论 重复进行TACE治疗HCC将加快肝纤维化发展趋势，在行TACE治疗时必须严格把握适应证。提出在行TACE的同时须加强护肝及肝纤维化逆转的治疗。     

肝切除和肝动脉化疗栓塞治疗原发性肝癌300例

对1985～1995年10年间收治的300例肝癌行肝切除106例,肝动脉化疗栓塞(HACE)194例。肝切除组术后的1、3、5年生存率分别为80.2％、30.2％和13.2％;而HACE组的6个月、1年生存率则分别为55.7％和32％。肝切除的疗效优于HACE,HACE后行二期肝切除者的1年生存率亦高于单纯HACE的病人。采用几项敏感的判断肝储备功能的指标,加上术中所见肝脏形态以及有无渗血和腹水,来综合评估肝储备功能和决定手术肝切除量,获得较好的效果。认为对高供血型肝癌采用HACE治疗有效。     

肝动脉灌注化疗栓塞治疗原发性中晚期肝癌48例

原发性肝癌(HCC)是我国常见的恶性肿瘤，近年来通过普查发现早期HCC的患者，进行以手术治疗为主的综合治疗，疗效显著提高。肝动脉栓塞灌注化疗(transeatheter arterial chemoembolization,TACE)是目前治疗中晚期HCC的有效手段。我们采用5-FU、丝裂霉素(MMC)、顺铂与碘化油充分混合行TACE治疗，取得良好效果。     

术前肝动脉化疗栓塞对肝癌切除术后疗效的影响

77例根治性肝细胞癌切除术，术前行肝动脉化疗栓塞26例(A组)，未栓塞51例(B组)。每组内再按肿瘤大小，分为Ⅰ(肿瘤3～8cm以下)、Ⅱ(肿瘤>8cm以下)两组。结果：术后1，2，3年无瘤存活率AⅠ分别为50.0％、33.3％，16．6％；BⅠ分别为72．7％、54.2％、39.7％;AⅡ分别为75.0％、56.2％、45．0％;BⅡ分别为38．9％、32.4％，10培％。其中AⅡ与BⅡ差别有显著性。1、3、5年存活率AⅠ85．7％、31.2％，0％;BⅠ84.8％，58．7%，27.9;AⅡ91.6％、82.5％，53．0％；BⅡ77.8％、30.1％、0％。其中AⅠ、BⅠ差别无显著性、AⅡ、BⅡ差别显著。结果提示对于8cm以下可切除肝细胞癌不宜行术前肝动脉化疗栓塞，>8cm肝细胞癌术前肝动脉化疗栓塞组术后复发率低，1、3、5年存活率高。     

术前经导管肝动脉化疗栓塞在原发性肝癌治疗中的价值

原发性肝细胞癌 (hepatocellular carcinoma,HCC)是我国最常见的恶性肿瘤之一 ,目前手术切除仍是治疗 HCC的最佳选择。虽然近年来由于诊断技术的不断改进以及利用超声和甲胎蛋白 (AFP)对高危人群普查 ,小肝癌检出率有所提高 ,但总的手术切除率仍不超过 30 % [1 ]。术后肝内复发率高达 6 0 %～75 %。大部分患者在诊断确立时 ,已丧失手术切除的机会。如何减少术后复发、使不能切除的肿瘤缩小后行二期切除是急待解决的问题。在众多的姑息疗法中 ,肝动脉化疗栓塞 (hepatic ar-terial chemoembolization,HACE)是最有效的治疗方法之一。自从…     

经导管肝动脉栓塞和肝动脉灌注化疗栓塞对原发性肝癌的介入效果

目的探究对原发性肝癌患者实施经导管肝动脉栓塞和肝动脉灌注化疗栓塞的疗效。方法以2012年1月至2015年8月我院106例原发性肝癌患者为观察对象,对此106例患者进行回顾性分析,共2组,观察组(56例,应用肝动脉灌注化疗栓塞治疗)、对照组(50例,应用经导管肝动脉栓塞治疗)。随访3年,对比两组患者的近期疗效、生存率、生存质量评分、中位生存时间、血清肿瘤标志物及毒副反应发生率。结果观察组患者客观缓解率(67.86%)明显高于对照组(42.00%),P0.05;观察组患者1年生存率(51.79%)、2年生存率(32.14%)、3年生存率(21.43%)略高于对照组(44.00%、24.00%、16.00%),但组间比较结果无显著差异,P0.05;观察组患者治疗后生存质量评分(70.45±0.78)分、中位生存时间(14.65±2.61)个月明显多于对照组(65.56±2.40)分、(12.12±2.23)个月,P0.05;观察组患者血清肿瘤标志物CEA、CA125、NSE及CA199均低于对照组,P0.05;两组患者毒副反应发生率无显著差异,P0.05。结论对原发性肝癌患者实施肝动脉灌注化疗栓塞治疗的近期疗效较经导管肝动脉栓塞治疗更佳,有助于提高患者生存质量评分,延长患者生存时间,但远期疗效无显著差异。     

肋间动脉参与肝癌供血的介入治疗研究

目的探讨经导管肋间动脉（intercostal artery,ICA）栓塞化疗的安全性。方法对24例经血管造影确认有ICA参与肝癌供血者进行经导管肝动脉栓塞化疗（transcatheter arterial chemoembolization,TACE）。巨块型15例,结节型9例。术前行CT或MRI平扫及增强扫描,术中行肋间动脉造影,将导管超选择至供血支进行栓塞化疗,并摄肝区碘油平片。观察术后临床经过、相关实验室检查和影像学表现,并与血管造影进行对照分析。结果病灶均位于肝右叶S6、S7段。参与肿瘤供血的ICA侧支均在T8（7.5%,3/40）,T9（15.0%,6/40）,T10（47.5%,19/40）和T11（30.0%,12/40）椎体水平右侧。22例肋间动脉TACE成功。治疗后复查CT显示87.5%（21/24）肝肿瘤完全被碘油充填,82.6%（19/23）血甲胎蛋白（AFP）下降至正常范围。3例术后肩部疼痛剧烈。1例术中皮肤瘙痒。5例术后出现皮肤红斑。结论ICA参与肝癌供血多见于多次行TACE并且肿块位于肝右叶S6、S7段的患者。肋间动脉TACE安全,但应警惕皮肤损伤并发症。     

Adjuvant Transcatheter Arterial Chemoembolization for Intrahepatic Cholangiocarcinoma after Curative Surgery: Retrospective Control Study

Background  

Effects of adjuvant transcatheter arterial chemoembolization (TACE) for intrahepatic cholangiocarcinoma (ICC) radical surgery have never been evaluated.     

Role of Preoperative Transcatheter Arterial Oily Chemoembolization for Resectable Hepatocellular Carcinoma

p < 0.05). A worse survival rate was particularly observed for the cirrhotic patients with TAOE than for those without TAOE: 35% and 72% at 4 years, respectively ( p < 0.01). As the cause of death, liver failure and gastrointestinal bleeding were more frequent in the patients with TAOE (13.3% versus 1.5%; p < 0.05). Although the TAOE seemed to retard intrahepatic recurrence during the first 1.5 years after operation (1.7% versus 10.3%; p < 0.05), the overall cancer death rate was similar between the two groups (18.3% versus 11.8%). Therefore we suggest that preoperative TAOE must not be performed for resectable HCC as a routine procedure, particularly in patients with cirrhosis. A prospective randomized trial is warranted to elucidate the merits and demerits of preoperative TAOE for surgically resectable HCC.     

Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization versus Portal Vein Embolization Only before Major Hepatectomy for Patients with Hepatocellular Carcinoma

Purpose

To evaluate the safety and efficacy of sequential transcatheter arterial chemoembolization (TACE) and portal vein embolization (PVE) prior to surgery in hepatocellular carcinoma (HCC) patients and to compare the clinical outcome of the combined procedure with that of a matched group of patients undergoing PVE alone.

Patients and Methods

From 1997 to 2008, 135 patients with HCC underwent sequential TACE and PVE (n = 71) or PVE alone (n = 64) before right hepatectomy. PVE was performed mean 1.2 months after TACE. In both groups, computed tomography (CT) and liver volumetry were performed before and 2 weeks after PVE to assess degree of left lobe hypertrophy.

Results

Baseline patient and tumor characteristics were similar in the two groups. After PVE, the chronological changes of liver enzymes were similar in the two groups. The mean increase in percentage future liver remnant (FLR) volume was higher in the TACE + PVE group (7.3%) than in the PVE-only group (5.8%) (P = 0.035). After surgery, incidence of hepatic failure was higher in the PVE-only group (12%) than in the TACE + PVE (4%) group (P = 0.185). Overall (P = 0.028) and recurrence-free (P = 0.001) survival rates were significantly higher in the TACE + PVE group than in the PVE-only group.

Conclusion

Sequential TACE and PVE before surgery is a safe and effective method to increase the rate of hypertrophy of the FLR and leads to longer overall and recurrence-free survival in patients with HCC.     

肝动脉化疗栓塞对原发性肝癌患者术后生存及复发的影响

目的探讨肝动脉化疗栓塞(TACE)对原发性肝癌(简称肝癌)术后患者生存及肿瘤复发的影响,为肝癌患者的临床诊治提供参考依据。方法选取我院2007年2月至2011年2月期间收治的220例原发性肝癌患者,依治疗方式分为TACE组与对照组,各110例,TACE组患者术后行TACE治疗,对照组患者术后未行TACE治疗,分析比较2组患者术后生存率与肿瘤复发率。结果 TACE组患者1、2、3年生存率分别为83.64%、56.36%和42.73%,对照组1、2、3年生存率分别为65.45%、40.91%和21.82%,TACE组患者的1、2、3年生存率均分别明显高于对照组(P<0.05)。TACE组患者1、2、3年肿瘤复发率分别为20.91%、54.55%和67.27%,对照组患者1、2、3年肿瘤复发率分别为38.18%、57.27%和70.91%,第1年肿瘤复发率TACE组明显低于对照组(P<0.05),但2、3年肿瘤复发率2组间比较,差异均无统计学意义(P>0.05)。结论肝癌患者术后行TACE可提高患者长期生存率,但并不能降低患者长期肿瘤复发率。     

Adjuvant Hepatic Arterial Infusion Chemotherapy after Hepatic Resection of Hepatocellular Carcinoma With Macroscopic Vascular Invasion

Background

The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection. We aimed to clarify the efficacy of adjuvant hepatic arterial infusion chemotherapy (HAI) for HCC with vascular invasion.

Methods

A total of 73 HCC patients with macroscopic vascular invasion were divided into two groups: 38 with hepatectomy with HAI (HAI group) and 35 with hepatectomy alone (non-HAI group). From 1997 to 2007, HAI was performed via an implanted injection port. The treatment comprised three courses of weekly infusion of HAI, which comprised cisplatin (10 mg daily on days 1–5) followed by 5-fluorouracil (5-FU; 250 mg daily on days 1–5) infusion. From 2007, cisplatin (60 mg/m²), 5-FU (600 mg/m²), and a mixture of mitomycin C (3 mg/m²) and degradable starch microspheres were administered for two courses.

Results

Overall, 92 % of patients completed adjuvant HAI. In the HAI and non-HAI groups, the 5-year disease-free survival (DFS) rates were 33.1 % and 11.8 %, respectively (p = 0.029), and the 5-year overall survival (OS) rates were 46.7 % and 32.7 %, respectively (p = 0.318). Among the patients with Vp3/4 or Vv3 (n = 32) in the HAI group, the 3-year DFS and OS rates were 33.7 % and 56.8 %, respectively (p = 0.049). Those in the non-HAI group were 8.3 % and 12.0 %, respectively (p = 0.023). Cox proportional multivariate analysis for DFS revealed that HAI was an independent favorable prognostic factor in all 73 patients (hazard ratio 0.536; p = 0.029).

Conclusions

Adjuvant HAI for HCC patients with vascular invasion might reduce the risk of recurrence.     

Hepatic Artery Chemoembolization for Hepatocellular Carcinoma in Patients Listed for Liver Transplantation

We retrospectively analyzed all listed patients having hepatic artery chemoembolization (HACE) for hepatocellular carcinoma (HCC) stage T2 or less. Outcomes were transplantation, waiting list removal, death, and HCC recurrence. Twenty patients (mean age 55.7 years; 15 males) were identified. Twelve (60%) were transplanted, seven (35%) were removed from the list and one (5%) remains listed. Fourteen (70%) are alive. All 12 transplanted patients are alive (mean 2.94 years); one of seven removed from the list is alive (mean 1.45 years). Survival was significantly higher for those transplanted or listed vs. removed from the list (100% vs. 14.3%, p = 0.0002). No HCC's recurred. Three patients (15%) were removed from the list after prolonged waiting times before MELD. Hepatic artery chemoembolization induced deterioration and removal from the list of one (5%) patient. Survival for those transplanted was excellent(100%), but overall survival was significantly lower (61.3%) at a mean 5.48 years. Hepatic artery chemoembolization for listed patients with 相似文献   

Optimal Strategy of Preoperative Transcatheter Arterial Chemoembolization for Hepatoblastoma

Purpose To investigate the optimal strategy of preoperative transcatheter arterial chemoembolization (TACE) for hepatoblastoma.Methods Between 1992 and 2001, 7 children with hepatoblastoma (aged 9 months to 13 years) underwent preoperative TACE. The chemoembolic agent used was an emulsion of pirarubicin and lipiodol. Four patients without distant metastasis underwent primary TACE without systemic chemotherapy. The other 3 with distant metastases underwent delayed TACE following systemic chemotherapy. These patients were all examined retrospectively using clinical data.Results The average dosage of lipiodol was 0.6ml per tumor maximal diameter (cm). All the primary cases showed a significant decrease in -fetoprotein (AFP) and a reduction in the tumor size. They consequently underwent a complete surgical resection and are now disease free. All the delayed cases showed a slight decrease in AFP and underwent complete surgical resection; however, two of them died of lung metastases, and the other died of a second malignancy. Regarding complications, liver dysfunction and pulmonary embolism occurred in one patient each.Conclusions For patients without distant metastasis, regardless of the resectability of the primary tumor, TACE may be considered the initial and only preoperative treatment, and it may be repeated. For patients with distant metastases, their complete eradication with systemic chemotherapy prior to TACE is essential.This paper was presented at the 33rd Meeting of the International Society of Paediatric Oncology (SIOP), Brisbane, Australia, October 10–13, 2001     

腹腔镜与开腹手术治疗原发性肝癌的围手术期情况比较

目的了解腹腔镜肝切除术（1aparoscopichepatectomy,LH）与开腹肝切除术（openhepatectomy,OH）治疗原发性肝癌的围手术期状况的变化。方法回顾性分析2012年1月至2013年6月期间青岛大学医学院附属医院肝胆外科收治的40例原发性肝癌患者的临床资料,其中20例行LH,20例行OH,比较2组患者的术前一般情况、术中情况和术后恢复情况。结果2组患者术前一般情况的差异均无统计学意义（P〉0．05）;在切口长度、术中出血量、术后肝功能指标、胃肠功能恢复情况和术后住院时间方面LH具有明显的优势（P〈0．05）,而在手术时间、术后并发症和住院总费用方面2组间差异无统计学意义（P〉0．05）。结论LH较传统的OH可明显改善肝癌患者的围手术期状况,值得在有条件的情况下开展推广。     

金龙胶囊联合经导管肝动脉化疗栓塞术治疗原发性肝癌的疗效和安全性的Meta分析

目的系统评价金龙胶囊联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌临床疗效和安全性。方法检索Cochrane Library、Embase、PubMed、OVID、Scopus、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普数据库和万方数据库,文献检索限定时间均从建库至2021年2月,纳入报道金龙胶囊联合TACE治疗原发性肝癌的随机对照试验,由两人独立筛选文献,提取数据及进行文献质量评价。运用RevMan 5.3软件对提取数据进行Meta分析。结果共纳入19项随机对照试验(共1740例患者),Meta分析结果显示:相比对照组,联合治疗组的客观缓解率更高[OR=2.23,95%CI(1.78,2.80),P <0.001],KPS评分[OR=2.59,95%CI(1.86,3.60),P <0.001],1年生存率[OR=1.77,95%CI(1.14,2.76),P=0.01]、2年生存率[OR=1.76,95%CI(1.12,2.75),P=0.01]优于对照组。此外,金龙胶囊还可提高机体免疫功能,减少不良反应的发生。结论金龙胶囊联合TACE可以提高原发性肝癌的疗效,提高患者的生活质量,减少不良反应的发生。但由于纳入的研究数量有限,金龙胶囊是否能改善肝癌患者长期生存率有待进一步研究,本研究结论尚需更多设计良好、严格执行的大样本随机对照双盲试验加以证实。